Hypertrophic cardiomyopathy in adult patients. Clinical course and prognostic factors in 119 patients;Miocardiopatía hipertrófica en el adulto. Curso clínico y factores pronósticos de 119 pacientes

Medicina Clinica

Volumn 123, Issue 1, 2004, Pages 1-4

  Candell Riera, Jaume ^a   Romero Farina, Guillermo ^a   Galve, Enrique ^a   Armadans, Lluís ^a   Palet, Jordi ^a   Castell Conesa, Joan ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Cardiomyopathy; Echocardiography; Nuclear medicine; Prognosis

Indexed keywords

ADULT; ARTICLE; CAUSE OF DEATH; CLINICAL TRIAL; DISEASE COURSE; DOPPLER ECHOGRAPHY; ELECTROCARDIOGRAM; EXERCISE TEST; FEMALE; FOLLOW UP; HEART ATRIUM ENLARGEMENT; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART MUSCLE PERFUSION; HEART VENTRICLE SEPTUM; HOLTER MONITORING; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; MORTALITY; POPULATION; PREDICTION; PROGNOSIS; RADIOISOTOPE VENTRICULOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUDDEN DEATH; SURVIVAL;

EID: 3142581375     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13063015     Document Type: Article

References (30)

1. Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy: clinical spectrum and treatment. Circulation 1995;92:1680-92.
2. Maron BJ. Hypertrophic cardiomyopathy. Lancet 1997;350:127-33.
3. Spirito P, Rapezzi C, Autore C, Bruzzi P, Bellone P, Ortolani P, et al. Prognosis in asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia. Circulation 1994;90:2743-7.
4. Maron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, Gohman TE, et al. Epidemiology of hypertrophic cardiomyopathy-related death. Revisited in a large non-referral-based patients population. Circulation 2000;102:858-64.
5. Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999;281:650-5.
6. Panza JA, Petrone RK, Fananapazir L, Maron BJ. Utility of continuous wave Doppler echocardiography in the noninvasive assessment of left ventricular outflow tract pressure gradient in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1992;19:91-9.
7. Yu EHC, Omran AS, Wigle ED, Williams WG, Siu SC, Rakowski H. Mitral regurgitation in hypertrophic cardiomyopathy: relationship to obstruction and relief with myectomy. J Am Coll Cardiol 2000;36:2219-25.
8. Sadoul N, Prasad K, Elliott PM, Bannerjee S, Frenneaux MP, McKenna WJ. Prospective prognosis assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 1997;96:2987-91.
9. Departament de Sanitat i Seguretat Social. Anàlisi de la mortalitat a Catalunya 1995. Barcelona: Departament de Sanitat i Seguretat Social, Generalitat de Catalunya, 1995.
10. McKenna WJ, Deanfield J, Faruqui A, England D, Oakley C, Goodwin J. Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol 1981;47:532-8.
11. Maron BJ, Cecchi F, McKenna WJ. Risk factors and stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy. Br Heart J 1994;72(Suppl):13-8.
12. Fananapazir L, Chang AC, Epstein SE, McAreavey D. Prognostic determinants in hypertrophic cardiomyopathy. Circulation 1992;86:730-40.
13. Álvarez-Auñón A, Candell-Riera J, Balda-Caravedo F, García del Castillo H, Soler Soler J. ¿Existen diferencias ecocardiográficas entre los pacientes sintomáticos y asintomáticos afectos de miocardiopatía hipertrófica? Rev Esp Cardiol 1988;41:143-7.
14. Elliot PM, Gimeno-Blanes JR, Mahon NG, Poloniecki JD, McKenna WJ. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopthy. Lancet 2001;357:420-4.
15. Spirito P, Bellone P, Harris KM, Bernabó P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000;342:1778-85.
16. Candell-Riera J, Romero-Farina G, Galve-Basilio E, Palet-Balart J, Armadans L, Reina MD, et al. Valor del ecocardiograma-Doppler en el pronóstico y en el seguimiento de la miocardiopatía hipentrófica. Rev Esp Cardiol 2001;54:7-15.
17. Von Dohlen TW, Prisant LM, Frank MJ. Significance of positive or negative thallium-201 scintigraphy in hypertrophic cardiomyopathy. Am J Cardiol 1989;64:498-503.
18. Dilsizian V, Bonow RO, Epstein SE, Fananapazir L. Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1993;22:796-804.
19. Romero-Farina G, Candell-Riera J, Pereztol-Valdés O, Castell J, Aguadé S, Galve E, et al. Papel del SPET miocárdico de perfusión y de la ventriculografía isotópica en pacientes adultos con miocardiopatía hipertrófica. Rev Esp Med Nuclear 2001;20:530-6.
20. Chikamori T, Dickie S, Poloniecki JD, Myers MJ, Lavander JP, McKenna WJ. Prognostic significance of radionuclide-assessed diastolic function in hypertrophic cardiomyopathy. Am J Cardiol 1990;65:478-82.
21. Cecchi F, Olivotto I, Montereggi A, Santoro G, Dolara A, Maron BJ. Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. J Am Coll Cardiol 1995;26:1529-36.
22. Kyriakidis M, Triposkiadis F, Anastasakis A, Theopistou A, Tocta R, Barbetseas J, et al. Hypertrophic cardiomyopathy in Greece. Clinical course and outcome. Chest 1998;114:1091-6.
23. Takagi E, Yamakado T, Nakano T. Prognosis of completely asymptomatic adult patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999;33:206-11.
24. Kofflard MJM, Ten Cate FJ, Van der Lee C, Van Domburg RT. Hypertrophic cardiomyopathy in a large community-based population: clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration. J Am Coll cardiol 2003;41:987-93.
25. Ruzyllo W, Chojnowska L, Demkow M, Witkowski A, Kusmierczyk-Droszcz B, Piotrowski W, et al. Left ventricular outflow tract gradient decrease with non-surgical myocardial reduction improves exercise capacity in patients with hypertrophic obstructive cardiomyopathy. Eur Heart J 2000;21:770-7.
26. Freedman RA. Use of implantable pacemakers and implantable defibrillators in hypertrophic cardiomyopathy. Curr Opin in Cardiol 2001;16:58-65.
27. Louie EK, Maron BJ. Hypertrophic cardiomyopathy with extreme increase in left ventricular wall thickness: functional and morphologic features and clinical significance. J Am Coll Cardiol 1986;8:57-65.
28. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003;348:295-3.
29. Beahrs MM, Tajik AJ, Seward GB, Giuliani ER, McGoon DC. Hypertrophic obstructive cardiomyopathy: ten to 21-year follow-up after partial septal myectomy. Am J Cardiol 1983;51:1160-6.
30. Malik MSA, Watkins H. The molecular genetics of hypertrophic cardiomyopathy. Curr Opin Cardiol 1997;12:295-302.